---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-024849"
form_type: "8-K"
ticker: "CTNM"
cik: "0001855175"
company_name: "Contineum Therapeutics, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:59:43.496958+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Contineum Q2 net loss $16M, cash $175.5M; PIPE-307 VISTA top line data Q4 2025

## Summary
- Net loss of $16.0M for Q2 2025 vs $9.0M in Q2 2024; R&D expenses $14.1M (+78% YoY).
- Cash and marketable securities $175.5M as of June 30, 2025; cash runway through 2027.
- PIPE-307 Phase 2 VISTA (RRMS) top line data expected Q4 2025; PIPE-791 PET data Q3 2025.
- Global PIPE-791 Phase 2 IPF trial initiation planned Q4 2025; PrMS and CTX-343 postponed.
- Johnson & Johnson Phase 2 Moonlight-1 trial of PIPE-307 in MDD recruiting 124 participants.

## SEC filing metadata
- accession: 0001437749-25-024849
- form_type: 8-K
- ticker: CTNM
- cik: 0001855175
- company_name: Contineum Therapeutics, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/0001437749-25-024849-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855175/000143774925024849/ctnm20250616_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-024849
- JSON: https://secwatch.observer/filing/0001437749-25-024849.json
- Plain text: https://secwatch.observer/filing/0001437749-25-024849.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.